Cigna Invests In GNS Healthcare Precision Medicine
Precision medicine company GNS Healthcare announced a $23m Series D round, led by Cigna Ventures. This latest round brings the company total funding to date to over $77m.
Established in 2000, the Cambridge-based company leverages AI to analyze both clinical trial and real-world data to model patient response to treatment and play out different ‘what if’ scenarios.
“We are thrilled to have Cigna contribute to our next phase of growth. As one of the largest and most forward-thinking global health services companies, Cigna is the perfect complement to our cadre of leading biopharma companies and health plan partners committed to improving patient outcomes through causal AI and the precision healthcare it enables.” – Colin Hill, Chairman, CEO and cofounder of GNS Healthcare.